Cerenome, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNSY research report →
Price Chart
About the company
Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs.
- CEO
- Marc H. Hedrick
- IPO
- 2026
- Employees
- 28
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on CNSY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $6.16M
- P/E
- -0.15
- Fwd P/E
- 1.13
- PEG
- 0.00
- P/S
- 1.47
- P/B
- -5.59
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 59.67%
- Op Margin
- -832.57%
- Net Margin
- -859.47%
- ROE
- -591.74%
- ROIC
- -960.53%
Latest fiscal year · YoY change
- Revenue
- $5.21M-10.5%
- Gross Profit
- $4.77M-4.1%
- Op Income
- $-15,298,000
- Net Income
- $-22,386,000-72.5%
- EPS
- $-7.19+85.3%
- OCF Growth
- -96.8%
- FCF Growth
- -94.8%
- 52W High
- $19.00
- 52W Low
- $0.43
- 50D MA
- $1.52
- 200D MA
- $4.20
- Beta
- 1.49
- RSI (14)
- 32
- Avg Volume
- 804.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cerenome reported early commercial traction in CNSide while keeping REYOBIQ clinical milestones on track, with management pointing to more data and broader commercialization in 2027.· November 16, 2026
- CNSide moved from claims submission to revenue recognition and cash collections, with October payer payments beginning.
- Third-quarter diagnostic revenue was about $0.7 million, while gross billings were $1.55 million on 222 tests.
- Management said CNSide coverage expanded to about 190 million covered lives and highlighted the new Aetna agreement.
- REYOBIQ met 3 of 4 2026 objectives, including closing enrollment in the GBM Phase II trial and advancing LM dose optimization.
- The company said it expects top-line data from the LM and GBM studies in mid-2027 and is planning a randomized Phase IIb LM study in the second half of 2027.
Total revenue for the quarter was $0.7 million, all from diagnostics, versus $1.4 million last year, which was all from grants. Cost of revenue was approximately $0.9 million. Research and development expense was $2.1 million, down from last year, while SG&A rose to $5.2 million from $3.4 million. Net loss was $8.7 million, or $1.14 per share, compared with $4.4 million, or $1.03 per share, in last year’s third quarter. For CNSide, Q3 gross billings were about $1.55 million on 222 tests, and management recognized $0.7 million of net diagnostic revenue; October cash collections were about $0.1 million. The company ended September with $4.9 million in cash, cash equivalents and investments, and it raised just under $4 million in October. Management reaffirmed 2026 guidance to exit the year at an annualized gross billing run rate of approximately $10 million to $12.5 million, and said CNSide could reach $20 million to $25 million of gross revenue by the end of 2027 if current trends continue. It also said the current access to the $20 million royalty and financing facility, if fully used, extends runway into 2028.
Marc Hedrick focused on execution across both the diagnostic and therapeutic businesses. He emphasized leadership additions, saying the company is building the commercial team now with an eye toward strong growth in 2027, while also highlighting progress in REYOBIQ and the completion of GBM enrollment. His tone was upbeat and operationally focused, with repeated references to being on track against the company’s 2026 goals.
Andrew Sims stressed that the company is still early in building a durable revenue and collections model for CNSide, so gross billings remain the clearest operating metric for now. He gave the key figures: $1.55 million in gross billings in Q3, $0.7 million in net diagnostic revenue, about $0.1 million in October cash collections, $4.9 million in quarter-end cash, and just under $4 million raised in October. He also said the company expects enough billing and collections history after 2 to 3 quarters to begin guiding to a go-forward revenue estimate, and that the royalty/financing facility could extend runway into 2028 if fully accessed.
Analysts asked when the LM study would next update and whether the readout would include overall survival, neurological response and quality of life; management said the next top-line update is expected in mid-2027 and should include progression-free survival, median overall survival, neurological function and quality of life. Another question focused on how MRI and CNSide tumor cell counts correlate; management said they often correlate but not perfectly, and pointed to an example where rising tumor cell counts preceded progression. Questions also covered the multi-dose versus single-dose REYOBIQ data, with management saying fractionation appears to break the prior dose ceiling while avoiding the marrow-related dose-limiting toxicities seen in earlier single-dose cohorts. On CNSide, management said it plans to start with 4 salespeople, expects them to be effective within about 90 days, and does not see capacity constraints after moving to a larger lab.
The call showed real commercial momentum: more institutions are ordering, repeat testing is rising, molecular profiling has launched, and payer coverage expanded to about 190 million lives. On the therapeutic side, management said REYOBIQ met most of its 2026 goals, the LM study has encouraging early safety/dosimetry data, and the company expects more meaningful clinical readouts in mid-2027.
CNSide is still early, with only $0.1 million in October cash collections and management not yet ready to provide formal 2027 revenue guidance. The company also posted a wider net loss and ended the quarter with limited cash, so continued funding needs remain relevant even with the recent financing and royalty facility. For REYOBIQ, efficacy endpoints are still not yet accessible for the LM study, and the next major data readouts are still months away.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- —
- Shares Outstanding
- 7.59M
- Float Shares
- 6.81M
of shares held by institutions
21 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 304.75K | 0 |
| Blackrock, Inc. | 99.56K | ▲ 3.58K |
| Geode Capital Management, LLC | 81.74K | ▲ 5.59K |
| Vanguard Fiduciary Trust Co | 36.87K | 0 |
| Ashton Thomas Private Wealth, LLC | 34.31K | 0 |
| State Street Corp | 30.85K | 0 |
| Northern Trust Corp | 14.61K | ▼ 904 |
| Xtx Topco Ltd | 11.55K | ▲ 11.55K |
| Ubs Group AG | 3.12K | ▲ 2.65K |
| Nuveen, LLC | 2.29K | ▲ 2.29K |
| Vanguard Global Advisers, LLC | 2.28K | 0 |
| Osaic Holdings, Inc. | 2.00K | 0 |
Held by 19 ETFs
Biggest fund positions in CNSY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | ANDREWS RONALD ASBURY | other | 92,858 |
| Oct 1, 26 | van Es-Johansson An | other | 921 |
| Oct 1, 26 | van Es-Johansson An | other | 921 |
| Oct 1, 26 | Hawkins Richard J | other | 921 |
| Oct 1, 26 | Hawkins Richard J | other | 921 |
| Oct 1, 26 | Sims Andrew John Hugh MacIntyre | other | 1,533 |
| Oct 1, 26 | Sims Andrew John Hugh MacIntyre | other | 1,165 |
| Oct 1, 26 | Sims Andrew John Hugh MacIntyre | other | 287 |
| Oct 1, 26 | Sims Andrew John Hugh MacIntyre | other | 287 |
| Oct 1, 26 | Sims Andrew John Hugh MacIntyre | other | 1,165 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNSY coverage
Recent articles, reports, and earnings notes.
No research on CNSY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNSY report →Cerenome, Inc. (CNSY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 16
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
globenewswire.com · Nov 16
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 13
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
globenewswire.com · Nov 13
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
globenewswire.com · Nov 12
Cerenome Appoints Director Ron Andrews as Chief Business Officer
globenewswire.com · Nov 10
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
globenewswire.com · Nov 4
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.